Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Stomach Neoplasms 14 Pancreatic Neoplasms 5 Colorectal Neoplasms 3 Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Biliary Tract Neoplasms 2 Advanced Solid Tumors 2 Advanced Non-Small Cell Lung Cancer 2 Uterine Cervical Neoplasms 1 Patients With Advanced or Metastatic Solid Tumors 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Pan-tumor 1 Neoplasm Metastasis 1 Locally Advanced Gastric or Gastroesophageal Junction Cancer 1 Klatskin Tumor 1 Gastric Adenocarcinoma 1 Gallbladder Neoplasms 1 Esophageal Squamous Cell Carcinoma 1 Colonic Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Transitional Cell 1 Bile Duct Neoplasms 1

Interventions

Temozolomide 1 S 1 (combination) 1 Oxaliplatin 1 Nivolumab 1 Capecitabine 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Pan-tumor × S 1 (combination) × Clear all

NCT04566380 2025-06-03

ONO-4538 Phase II Rollover Study (ONO-4538-98)

Ono Pharmaceutical Co., Ltd.

Phase 2 Recruiting

Pan-tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡